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Introduction: Most patients with sepsis and acute lung injury require mechanical ventilation to improve
oxygenation and facilitate organ repair. Mast cells are important in response to infection and resolution of tissue
injury. Since tryptase secreted from mast cells has been associated with tissue fibrosis, we hypothesized that
tryptase would be involved in the early development of ventilator-induced pulmonary fibrosis in a clinically relevant
model of sepsis-induced lung injury.
Methods: Prospective, randomized, controlled animal study using Sprague-Dawley rats. Sepsis was induced by cecal
ligation and perforation. Animals were randomized to spontaneous breathing or two ventilatory strategies for 4 h:
protective ventilation with tidal volume (VT) = 6 ml/kg plus 10 cmH2O positive end-expiratory pressure (PEEP) or
injurious ventilation with VT = 20 ml/kg plus 2 cmH2O PEEP. Healthy, non-ventilated animals served as non-septic
controls. We studied the following end points: histology, serum cytokine levels, hydroxyproline content, tryptase
and proteinase-activated receptor-2 (PAR-2) protein level in lung homogenates, and tryptase and PAR-2
immunohistochemical localization in the lungs.
Results: All septic animals developed acute lung injury. Animals ventilated with high VT had a significant increase
of pulmonary fibrosis, hydroxyproline content, tryptase and PAR-2 protein levels compared to septic controls
(P <0.0001). However, protective ventilation attenuated sepsis-induced lung injury and decreased lung tryptase and
PAR-2 protein levels. Immunohistochemical staining confirmed the presence of tryptase and PAR-2 in the lungs.
Conclusions: Mechanical ventilation modified tryptase and PAR-2 in injured lungs. Increased levels of these proteins
were associated with development of sepsis and ventilator-induced pulmonary fibrosis early in the course of
sepsis-induced lung injury.Introduction
Acute lung injury during the acute respiratory distress
syndrome (ARDS) complicates a variety of clinical con-
ditions and is associated with significant morbidity and
mortality [1]. Sepsis, the most common cause of ARDS,
promotes or interferes with mechanisms involved in tissue
repair [2]. Mechanical ventilation (MV) is an essential life* Correspondence: jesus.villar54@gmail.com
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ventilator strategy is the only proven treatment for im-
proving survival [3]. However, MV can cause or aggravate
lung injury, an entity referred to as ventilator-induced
lung injury (VILI) [4]. Experimental and clinical studies
[3-6] have provided insights into the physiology of VILI,
demonstrating that some patterns of MV result in pul-
monary and systemic changes that mimic ARDS and
sepsis [2-4]. Many ARDS patients survive the underlying
disease but die with pulmonary fibrosis [7,8]. Recent
reports suggest that sepsis may trigger the development of
persistent fibrosis [9] and that VILI may be a major con-
tributor to lung fibrosis [10,11].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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poorly understood. Pulmonary fibrosis appears to be an
important determinant of mortality, regardless of the
cause of ARDS [11,12]. Areas of fibrosis are adjacent to
inflammation in the early exudative phase of ARDS
[13-15]. A feature of lungs in patients with fibrotic lung
disease is the increased number of mast cells [16] and it
has been suggested that mast cells may support the con-
tinuation of the fibroproliferative process in patients
with ARDS [17] by release of mediators. The most abun-
dant product of mast cells is tryptase, a serine protease
with pleiotropic biological activities [18]. Tryptases con-
sist of α-tryptase and β-tryptase [19]. β-tryptase is the
main isoenzyme expressed in human lung. Tryptase
upregulates the expression of cytokines [19] and vascular
endothelial growth factor (VEGF) [20]. We have previ-
ously reported that MV modulates the innate immune
response by interfering with Toll-like receptors [6] and
increases VEGF by activating the Wnt/β-catenin signal-
ing pathways [10]. Tryptase is a potent stimulant of the
synthesis of type I collagen by fibroblasts [21]. The
mechanism by which tryptase exerts its effects is by acti-
vating a member of the protease-activated receptor
(PAR) family, PAR-2 [22]. Currently, no published re-
ports have examined the changes of tryptase and PAR-2
in the context of septic ARDS and VILI. We tested the
hypothesis that tryptase content is modulated by MV
and could contribute to the early development of pul-
monary fibrosis in an experimental, clinically relevant
animal model of sepsis-induced acute lung injury.
Material and methods
This protocol was approved by the Animal Care Com-
mittee at the Hospital Universitario Dr. Negrín (CEEBA-
003/10), in accordance with the European Commission
Directive 2010/63/EU for animal experimentation. This
study followed the ARRIVE guidelines for reporting pre-
clinical animal research [23].
Animal preparation and experimental protocol
A total of 40 male Sprague-Dawley rats (300 to 350 g)
were included. Animals were anesthetized with an intra-
peritoneal injection of ketamine hydrochloride (80 mg/
kg) and xylazine (8 mg/kg) [24]. Animals were initially
randomized to two groups: non-septic controls (n = 6)
and septic (n = 34). Sepsis was induced by cecal ligation
and perforation (CLP). CLP is considered the gold stand-
ard model for experimental sepsis [25]. A detailed de-
scription of this model is provided elsewhere [26]. All
septic animals received 10 ml normal saline subcutane-
ously immediately after CLP for postoperative fluid re-
suscitation. Eighteen hours after CLP, the peritoneal
cavity was reopened in surviving animals and the cecum
was excised and removed distal to the ligature. We thenwashed the peritoneal cavity with 20 ml warm, normal
saline, and gently squeezed the abdomen several times.
After closing the abdomen, each animal received 10 ml
normal saline subcutaneously for fluid resuscitation
throughout the experimental period. Then, animals were
randomized to spontaneous breathing or two strategies
of MV for 4 h: (i) protective MV using a tidal volume
(VT) of 6 ml/kg plus 10 cmH2O of positive end-
expiratory pressure (PEEP) or (ii) injurious MV using a
VT of 20 ml/kg plus 2 cmH2O PEEP. We used a VT of
20 ml/kg because it produces regional lung stretch com-
parable to that experienced by ARDS patients in nonde-
pendent areas of the lung [26,27]. In previous pilot
experiments, we found that the minimal level of overdis-
tension in healthy rats causing an identifiable lung injury
is 20 ml/kg. Healthy, anesthetized, non-ventilated ani-
mals served as non-septic controls.
In animals assigned to MV, we performed a tracheot-
omy using a 14-G Teflon catheter. Animals were then
paralyzed (1 mg/kg pancuronium bromide), connected
to a time-cycled, volume-limited rodent ventilator
(Ugo Basile, Varese, Italy) and placed on a temperature-
controlled table to maintain body temperature at 37°C.
Fraction of inspired oxygen (FiO2) was 0.60 in both MV
groups. Ventilator rate was set at 90 cycles/min and 30
cycles/min in the low and high VT groups, respectively, to
maintain constant minute ventilation and comparable
partial pressure of carbon dioxide (PaCO2), based on our
previous experiments with the same animal model and
identical setup [24]. Animals were monitored noninva-
sively to minimize the possibility of triggering an in-
flammatory response, after establishing a protocol that
provided hemodynamic stability and comparable arterial
blood gases. Animals were ventilated supine on a restrain-
ing board inclined 20° from the horizontal, and received
intermittent intraperitoneal boluses of anesthetic and
paralytic agents during the 4-h experimental period. Peak
airway pressures were continuously monitored. Oxygen
saturation was continuously measured using a pulse oxy-
meter applied to the rat's tongue.
Histological examination
At the end of the 4-h observation and ventilation period,
animals were sacrificed by supplemental pentobarbital
(10 mg/kg), followed by exsanguination by cutting the
abdominal vessels. The lungs were removed from the
chest, the trachea cannulated, and the right lung was
fixed by intratracheal instillation of 3 ml 10% formalin.
Two pathologists (FV, SGH) blinded to group identity
examined random sections of the lung from each animal
with particular reference to alveolar and interstitial damage
defined as the presence of cellular inflammatory infiltrates,
pulmonary edema, disorganization of lung parenchyma,
alveolar rupture and hemorrhage. A semiquantitative
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scoring from 0 to 4 (none, mild, moderate, severe, very
severe) for each parameter. A total histological lung in-
jury score [13] was obtained by adding the individual
scores in every animal and averaging the total values in
each group.
Histological features of lung fibrosis were evaluated
with Masson-Goldner staining under light microscopy
(Nikon Optiphot, Tokyo, Japan) and photographed with
a Nikon Digital DS-5 M camera. Three longitudinal and
random slides from each animal were used for analysis
according to the method by Ashcroft et al. [28]. Each
successive field was individually assessed for fibrosis
using a semiquantitative score as follows: 0 = normal
lung; 1 = minimal fibrous thickening of alveolar or bron-
chiolar walls; 2 = moderate thickening of walls without
obvious damage to lung architecture; 3 = increased fi-
brosis with definite damage to lung structure and forma-
tion of fibrous bands or small fibrous masses; 4 = severe
distortion of structure and large fibrous areas; 5 = total
fibrous obliteration of the field. After examining all sec-
tions, a total score was calculated for each animal.
Cytokine serum levels
At the end of the 4-h experimental period, 2 ml of blood
were collected from the first six surviving rats in each
group by cardiac puncture. After centrifugation for 15
min at 3,000 rpm, sera were divided into aliquots and
frozen at −80°C. Tumor necrosis factor alpha (TNF-α)
and interleukin 6 (IL-6) protein concentrations were
measured by commercially available immunoassays (Cyto-
screen, Biosource International, Camarillo, CA, USA) and
performed according to the manufacturer’s specifications
using an ELx800 NB Universal Microplate Reader (BioTek
Instruments, Winooski, VT, USA). TNF-α and IL-6 con-
centrations are expressed as pg/ml.
Hydroxyproline assay
Collagen synthesis is determined by a hydroxyproline
assay [20]. Lung samples were homogenized in 2 ml
phosphate-buffered saline (PBS), and 1 ml aliquot was
hydrolyzed with 6 N HCl at 110°C for 18 h following the
Woessner method [29]. Then, 25 μL aliquots were added
to 1 ml of 1.4% chloramine T (Sigma-Aldrich, St Louis,
MO, USA), 10% 2-propanol, and 0.5 M sodium acetate,
pH 6.0. After 20 min of incubation at room temperature,
1 ml Erlich's solution (1 M p-dimethyl-amino-benzalde-
hyde in 70% 2n-propanol and in 20% perchloric acid)
was added, followed by a15-min incubation at 65°C.
Samples were read in a spectrophotometer (ELx800
Absorbance Microplate Reader, BioTek Instrument,
Luzen, Switzerland). The amount of hydroxyproline was
determined against a standard curve. Data are expressed
as μg/g of lung tissue.Immunoblotting
Left lungs from all experimental groups were excised,
washed with saline, frozen in liquid nitrogen, and stored
at −80°C for subsequent protein extraction and immu-
noblotting. Lungs were sampled in multiple areas, homog-
enized, and proteins were extracted by centrifugation at
14,000 rpm for 5 min at 4°C. Protein concentration was
determined using the Bio-Rad DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA, USA). The supernatant (30
μg protein) was mixed with equal volume of 2 × SDS sam-
ple buffer and boiled for 5 min. Proteins were separated
by SDS-polyacrylamide gel electrophoresis and transferred
onto PVDF membranes. Blots were blocked for 1 h
with 10% (w/v) dry non-fat milk in Tris-buffered sa-
line (TBS)-Tween and probed with rabbit polyclonal
primary anti-tryptase and anti-PAR-2 antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), followed by
a goat anti-rabbit immunoglobulin G (IgG)-horseradish
peroxidase (HRP) as secondary antibody (Santa Cruz
Biotechnology). Blots were then stripped and reprobed
with a β-actin antibody (Cell Signaling Technology,
Danvers, MA, USA) to confirm equal protein loading.
Quantification of blots was performed using the Scion
Image software package (Scion Corp., Frederick, MD,
USA).Immunohistochemistry
Lungs were fixed in 4% formaldehyde, paraffin embed-
ded, sliced into 3-μm sections, deparaffinized, and anti-
gen unmasked in citrate buffer solution (0.01 M pH 6.0).
Then, endogenous peroxidase activity was blocked for
10 min at room temperature with 0.3% H2O2. Slides
were incubated with rabbit primary anti-tryptase and anti-
PAR-2 antibodies (Santa Cruz Biotechnology) in PBS for 1
h and with biotinylated anti-rabbit IgG secondary anti-
bodies for 10 min at room temperature, and detected by
the peroxidase-conjugated avidin-biotin complex reaction
with 3-amino-9-ethylcarbazole AEC+/substrate chromogen
(Dako, Hamburg, Germany). Sections were then counter-
stained with Mayer’s hematoxylin (Dako). Images were ob-
tained using an Olympus (BX50) microscope (Olympus,
Hamburg, Germany) and an Olympus digital camera.Statistical methods
For sample size calculations, we estimated a minimum
of six animals per each subgroup to detect an absolute
increase of 50% in the levels of fibrotic markers in the
high-VT group, with an alpha = 0.05 and power >0.80.
Data are expressed as mean ± standard deviation (SD).
Groups were compared using a one-way analysis of vari-
ance followed by Bonferroni post hoc testing where ap-
propriate. A two-sided P value <0.05 was considered
statistically significant.
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Outcome and pathological evaluations
A total of seven rats died after CLP. The remaining 27
septic animals were randomly allocated to three groups
(n = 9 in each group). Within the 4-h observational
period, three septic animals died in the non-ventilated,
spontaneous breathing group. No animals ventilated
with protective MV died; one animal ventilated with
high VT died. Only data from animals surviving the 4-h
experimental period were analyzed. At the end of the 4-h
MV period, peak inspiratory pressure was 28 ± 2 cmH2O
in the high-VT group and 20 ± 2 cmH2O in the low-VT
group (P <0.0001).
Histological examination of septic lungs revealed the
presence of acute lung injury and pulmonary fibrosis
(Figure 1A). Septic animals ventilated with high VT had
the highest histological injury scores (14.9 ± 1.5), whereas
CLP animals ventilated with low VT had a lower his-
tological injury score than non-ventilated CLP animals
(5.5 ± 0.6 vs. 10.1 ± 1.0) (P <0.0001). The high-VT MV
group had the highest lung fibrosis score (3.8 ± 0.3 vs. 2.3 ±
0.3 in septic, non-ventilated animals, P <0.001). By contrast,
low-VT MV attenuated the degree of lung fibrosis (1.4 ±
0.2) (P <0.001).
Hydroxyproline content
Sepsis increased hydroxyproline levels (284 ± 38 μg/g) in
the lungs when compared to healthy controls (P <0.01).
Hydroxyproline content was higher in animals venti-
lated with high VT (347 ± 94 μg/g) than with low VT
(99 ± 35 μg/g) (P <0.0001) (Figure 1B).Figure 1 Histological features of lung fibrosis and hydroxyproline con
acute lung injury induced by sepsis and mechanical ventilation. Collagen d
high-VT ventilated lungs (Masson-Goldner, ×400 magnification). (B) Hydrox
spontaneous breathing; S: septic, anesthetized, non-ventilated, spontaneou
positive end-expiratory pressure (PEEP) of 10 cmH2O; SHVT: septic, ventilate
¶P <0.01 vs. S; *P <0.01 vs. C; ***P <0.0001 vs. SLVT + PEEP. VT, tidal volume.Serum cytokines
Systemic levels of cytokines were higher in high-VT MV
septic animals (n = 8) than in low-VT animals (n = 9):
TNF-α 130 ± 35 vs. 18 ± 9 pg/ml, P <0.0001; IL-6 2,209 ±
618 vs. 344 ± 98 pg/ml, P <0.0001, respectively. In non-
ventilated septic animals (n = 6), TNF-α was 53 ± 10 pg/
ml and IL-6 was 1,353 ± 542 pg/ml (Figure 2).
Tryptase and PAR-2 protein levels and immunohistochemical
staining
Tryptase and PAR-2 protein levels increased in all septic
groups. The highest tryptase and PAR-2 protein levels
were found in the lungs of septic animals ventilated with
high VT (7.89 ± 0.44 vs. 5.64 ± 0.53 in septic, non-
ventilated animals, P <0.001 for tryptase; 3.36 ± 0.04 vs.
2.32 ± 0.12, P <0.001 for PAR-2) (Figures 3 and 4).
Tryptase and PAR-2 proteins (Figure 5) were predom-
inantly expressed in mast cells and fibroblasts respect-
ively. Control, healthy animals had low staining for
tryptase and PAR-2. There was an intense expression of
these peptides in the lungs of the high-VT group.
Discussion
To our knowledge, this is the first report to provide evi-
dence that the application of MV modifies tryptase and
PAR-2 levels in the septic injured lung. Our main find-
ings are: (i) protein content of tryptase of septic lungs
after a short period of injurious MV was associated with
a more than threefold increase of hydroxyproline com-
pared to protective ventilation; and (ii) an injurious
MV strategy increases pulmonary tryptase and collagentent in lungs. (A) Pathological features of lung fibrosis in rats with
eposition (see arrows) was marked in septic, non-ventilated and
yproline content in the lungs. C: healthy, anesthetized, non-ventilated,
s breathing; SLVT + PEEP: septic, ventilated with low tidal volume plus
d with high tidal volume. Six animals were quantified in each group.
Figure 2 Serum levels of tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6 in non-ventilated and mechanically ventilated septic
animals. C: healthy, anesthetized, non-ventilated, spontaneous breathing; S: septic, anesthetized, non-ventilated, spontaneous breathing; SLVT +
PEEP: septic, ventilated with low tidal volume plus positive end-expiratory pressure (PEEP) of 10 cmH2O; SHVT: septic, ventilated with high tidal
volume. Eight animals were quantified in each group. ***P <0.0001 vs. S and SLVT + PEEP.
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Our findings support the hypothesis that tryptase and
collagen lung content is modulated by MV and could
contribute to the early development of pulmonary fibrosis
in an experimental, clinically relevant animal model of
sepsis-induced acute lung injury.Figure 3 Western blot analysis of tryptase. The upper panel is a
representative gel for each experimental group. The lower panel
represents the relative optical density of tryptase normalized against
β-actin. C: non-septic, anesthetized, non-ventilated, spontaneous
breathing; S: septic, anesthetized, non-ventilated, spontaneous
breathing; SLVT + PEEP: septic, ventilated with low tidal volume plus
positive end-expiratory pressure (PEEP) of 10 cmH2O; SHVT: septic,
ventilated with high tidal volume. Six animals were quantified in
each group. #P < 0.01 vs. S; ¶P <0.001 vs. S.MV causes injury not only by structural disruption of
the lung but also by inducing the release of mediators
that can worsen lung damage and may cause multiorgan
dysfunction [2]. Alveolar overdistension and cyclic re-
cruitment and collapse of unstable lung units are theFigure 4 Western blot analysis of PAR-2. The upper panel is a
representative gel for each experimental group. The lower panel
represents the relative optical density of tryptase normalized against
β-actin. C: non-septic, anesthetized, non-ventilated, spontaneous
breathing; S: septic, anesthetized, non-ventilated, spontaneous
breathing; SLVT + PEEP: septic, ventilated with low tidal volume plus
positive end-expiratory pressure (PEEP) of 10 cmH2O; SHVT: septic,
ventilated with high tidal volume. Six animals were quantified in
each group. ¶P <0.001 vs. S.
Figure 5 Immunohistochemical localization of tryptase and PAR-2. Brown color staining indicates positive staining and blue/violet indicates
nuclei counterstained with hematoxylin. Tryptase and PAR-2 staining increased markedly in high-VT lungs. C: non-septic, anesthetized, non-ventilated,
spontaneous breathing; S: septic, anesthetized, non-ventilated, spontaneous breathing; SLVT + PEEP: septic, ventilated with low tidal volume plus
positive end-expiratory pressure (PEEP) of 10 cmH2O; SHVT: septic, ventilated with high tidal volume. ×400 magnification. PAR-2, protease-activated
receptor-2; VT, tidal volume.
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[30]. The importance of minimizing overdistension is
supported by a compelling physiological rationale and by
strong clinical evidence [3]. Given the reduced volume
of ARDS lungs [31], low-VT ventilation plus moderate-
to-high levels of PEEP contribute to lung protection as
both mediate reductions in shear/strain stresses by dis-
tinct mechanisms [30]. MV has been shown to activate
extracellular matrix elements such as collagen and pro-
teoglycan [32]. Collagen is the most abundant stress-
bearing component of the parenchymal tissue and plays
a key role in determining the mechanical properties and
cellular responses to injury [33]. The amount of collagen
in the lung is tightly regulated to ensure a strict balance
between synthesis and degradation. Human studies sug-
gest that collagen content in the lung is a key determin-
ant of active fibroproliferation or normal repair [34].
There is evidence of fibrotic changes in the earliest
stages of ARDS [11,14,15]. Any alteration in the collagen
content in the ARDS lung may contribute to cellular ab-
normalities and fatal outcome [8,34]. We have recently
reported that the WNT/β-catenin signaling, a pathway
known to induce fibroblast activation and collagen syn-
thesis [35], is activated very early in sepsis-induced acute
lung injury [36].
The exact mechanism regulating tryptase activity is
unknown. Release of tryptase, proteoglycans, and cyto-
kines from mast cells (known as degranulation), may be
induced by physical and immune mechanisms [37].
Tryptase-containing mast cells from the lung are found
mainly in alveolar walls. PAR-2, the specific cell surface
receptor for tryptase [38], is expressed by airway epithe-
lial and smooth muscle cells, endothelial and vascular
smooth muscle cells, terminal bronchial epithelium, type
II cells and mast cells within the respiratory tract [39].
Mast cells induce fibroblasts to proliferate and synthesizetype I collagen. Mast cells are difficult to locate in rou-
tinely processed lung specimens because they often lose
their characteristics staining properties with formalin fix-
ation. However, they can be identified using immunohisto-
chemical localization of tryptase [40].
The term ‘fibroproliferative’ has been conventionally
applied only to ‘late-phase ARDS’, but pulmonary fibro-
proliferation can occur early in ARDS and is correlated
with outcome [15,34]. Although in our animal model the
exudative stage of acute lung injury and VILI is domi-
nated by the presence of edema and inflammatory infil-
trates [6], increased collagen was present in all lung
samples at 18 h after CLP and increased further after 4 h
of high-VT MV, confirming our previous results [10,13].
In lung tissues from 17 ARDS patients, Liebler et al. [17]
found that 80% of samples from the early exudative stage
exhibited increased number of myofibroblasts, and 50%
had increased number of procollagen type I-producing
cells. Ichikado et al. [15] evaluated 85 ARDS patients
using high-resolution computed tomography within the
first day of ARDS diagnosis, and found that 47% of them
had radiological areas indicative of fibroproliferation. Pa-
tients with less fibroproliferative changes on scans had a
significantly lower mortality and more ventilator-free days
than those with more extensive areas of fibroproliferation
on day 1, despite the fact that both groups were ventilated
with a mean VT of 8 ml/kg predicted body weight and 8
cmH2O of PEEP.
Our findings have two major clinical implications.
First, alveolar overdistension is a driver for the develop-
ment of pulmonary fibrosis since protective MV was
able to attenuate the fibroproliferative response. We
recently demonstrated that TGF-β and wingless-type in-
tegration site family, member 5A (WNT5A) activation
are also important mechanisms involved in lung fibrosis
after MV in murine models of acute lung injury and VILI
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dependent on the severity of VILI in a two-hit in vivo
mouse model of acid aspiration-induced lung injury
followed by a MV strategy causing lung overdistension
[14]. Second, it is plausible that pharmacological strategies
aimed directly at attenuating the fibroproliferative re-
sponse may enhance the transition to a normal repair
process and, hopefully, improve survival of ARDS. Select-
ive inhibition of lung tryptase or PAR-2 may be potential
pharmacological targets to inhibit the early fibroprolifera-
tion that occurs by mechanical overdistension in ARDS.
Akers et al. [22] demonstrated that tryptase-induced
fibroblast proliferation can be inhibited by proteolytic in-
hibitors, and that human or rat PAR-2 mimicked the pro-
liferative effects of tryptase. Taken together, these data
suggest that tryptase induces proliferation of lung fibro-
blast by activating PAR-2. Recently developed tryptase and
PAR-2 antagonist compounds have been shown to inhibit
the tryptase- and PAR-2-induced tissue responses [41,42],
representing a novel therapeutic approach for preventing
and treating ventilator- and ARDS-induced pulmonary fi-
brosis. Further research in these areas is needed since the
potential for tryptase and PAR-2 inhibitors to attenuate
MV-induced fibrosis is unknown.
Our study has some limitations. First, although we
showed that MV modulated tryptase/PAR-2 protein
levels in the context of a clinically relevant model of
sepsis-induced lung injury, our data do not confirm that
this is a major pathway responsible for the MV-induced
pulmonary fibrosis since we did not examine the effect
of disrupting tryptase/PAR-2 protein levels by specific
inhibitors or use tryptase/PAR-2-deficient animals. How-
ever, using a rat model of ARDS induced by intestinal
ischemia-reperfusion injury, Gan et al. [43] found that the
development of lung injury was accompanied with con-
comitant increases of tryptase and PAR-2 expressions in
the lungs. They also demonstrated that by inhibiting tryp-
tase, lung injury was reduced while activating mast cells
further aggravated lung damage. In addition, other investi-
gators have found that tryptase-deficient animals are less
susceptible than their wild-type counterparts to lung in-
jury and fibrosis under experimental conditions [44]. Also,
in PAR-2 knockout mice, PAR-2 deficiency reduced the
progression of liver fibrosis, hepatic collagen gene expres-
sion and hydroxyproline content [45]. Second, further
mechanistic studies need to be done to elucidate the mol-
ecules and pathways involved in lung protection with re-
gard to ARDS/fibrosis during low-VT ventilation. Finally,
we have not examined whether PAR-2 could be activated
by other proteases, such as coagulation factor Xa [46].
Conclusions
Our experimental findings provide evidence for an asso-
ciation between acute lung injury, tryptase, PAR-2, andpulmonary fibrosis in VILI and sepsis-induced lung in-
jury. Further studies are needed to fully address whether
the attenuation or inhibition of tryptase and/or PAR-2
may offer a potential clinical therapeutic option in the
setting of VILI and sepsis-induced ARDS.
Key messages
 Changes in tryptase and collagen lung content
during sepsis-induced acute lung injury are
dependent on the mechanical ventilation strategy.
 Increased expression of tryptase and collagen
induced by alveolar overdistension may be
important events contributing to the development of
ventilator-induced pulmonary fibrosis.
 Attenuation or inhibition of tryptase and/or PAR-2
may offer a potential clinical therapeutic option in
the setting of VILI and sepsis-induced ARDS.
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